Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Published version of a preprint
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Immunotherapy has recently entered a renaissance phase with the approval of multiple agents for the treatment of cancer. Immunotherapy stands ready to join traditional modalities, including surgery, chemotherapy, radiation, and hormone therapy, as a pillar of cancer treatment. Although immunotherapy has begun to have success in advanced cancer treatment, its scheduling and efficacy with surgery to treat earlier stages of cancer and prevent distant metastases have not been systematically examined. Here, we have used two models of spontaneously metastatic breast cancers in mice to illustrate the significantly greater therapeutic power of neoadjuvant, compared with adjuvant, immunotherapies in the context of primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. These data now provide a strong rationale to extensively test and compare neoadjuvant immunotherapy in humans. Significance: We demonstrate the significantly greater therapeutic efficacy of neoadjuvant, compared with adjuvant, immunotherapies to eradicate distant metastases following primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. Cancer Discov; 6(12); 1382–99. ©2016 AACR. See related commentary by Melero et al., p. 1312. This article is highlighted in the In This Issue feature, p. 1293
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Data from a landmark study using an orthotopic model of breast cancer showed that neoadjuvant ICIs might outperform adjuvant ICIs106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
In the citing paper
“Delivering ICIs after surgery enabled T cell expansion, and yielded the best antitumour activity while also decreasing toxicity106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cited by
Items 501–600 of 930
Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer
Hirmas, N., Holtschmidt, J., & Loibl, S. (2024) · Cancers · doi:10.3390/cancers16183236 · Cited by 11
“This is particularly true for patients with TNBC and HR-positive/HER2-negative breast cancer, which suggests that germline BRCA1/2 testing should be considered prior to treatment start.”
BackgroundBrunelli, A., Hoffman, R., Wotton, R., Baijal, S., Jain, P., Clarke, K., Escriu, C., Fakih, O., Franks, K., Lodhia, J. V., et al. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.12.010 · Cited by 10
Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma
Pilie, P. G., & Jonasch, E. W. (2017) · Kidney Cancer · doi:10.3233/kca-170009 · Cited by 10
“Preclinical studies have shown a signal for increased efficacy of modern immunotherapy in the neoadjuvant setting compared to adjuvant setting due to increased, sustained activation of T cell antitumor activity with an effector/memory phenotype [36].”
Filipska, M., Pedraz‐Valdunciel, C., CHAIB-OUKADOUR, I., & Rosell, R. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1582635 · Cited by 10
“Moreover, following the results from breast cancer patients, it has been evaluated whether neoadjuvant immunotherapy could also be of benefit to lung cancer patients [91].”
BackgroundJacoberger-Foissac, C., Saliba, H., Wantz, M., Seguin, C., Flacher, V., Frisch, B., Heurtault, B., & Fournel, S. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.05.026 · Cited by 10
Primary and metastatic breast tumors cross-talk to influence immunotherapy responses
Oliver, A. J., Keam, S. P., von Scheidt, B., Zanker, D. J., Harrison, A. J., Tantalo, D. G. M., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1802979 · Cited by 10
“Studies of the 4T1 model have demonstrated that immunotherapy administration before surgical resection of a primary breast tumor leads to decreased lung metastases and enhanced survival of mice compared to mice treated with immunotherapy in the adjuvant setting.(38,39) As in our model, the presence of the primary tumo…”
BackgroundTang, W., Xu, W., Huang, W., Lin, G., Zeng, Y., Lin, J., Wu, M. J., Bao, H., Peng, J., Jiang, H., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13910 · Cited by 10
Personalizing Oncolytic Immunovirotherapy Approaches
Stergiopoulos, G. M., Iankov, I. D., & Galanis, E. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00689-4 · Cited by 10
Perioperative immunotherapy for muscle-invasive bladder cancer
Kim, I.-H., & Lee, H. J. (2020) · Translational Andrology and Urology · doi:10.21037/tau.2019.11.31 · Cited by 11
Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art
Saux, O. L., Lounici, Y., Wajda, P., Ghamry-Barrin, S., Caux, C., Dubois, B., & Ray-Coquard, I. L. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103172 · Cited by 10
Li, F., Chen, Y., Wu, J., Li, C., Chen, S., Zhu, Z., Qin, W., Liu, M., Hu, B., Liu, S., et al. (2022) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.19 · Cited by 11
Zhao, D., Xu, L., Wu, J., She, Y., Su, H., Hou, L., Haoran, E., Zhang, L., Grossi, F., Subramanian, M. P., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-476 · Cited by 10
“Incorporating ICI and chemotherapy into the management of early-stage NSCLC is attractive because the primary tumor may release neoantigens from dying tumor cells and activate tumor-specific T cells before surgical resection (8,9).”
Ma, T., Wen, T., Xu, C., Wang, Y., Wei, P., Yang, B., Yi, L., Wang, X., Yan, Z., Wang, J., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.08.002 · Cited by 11
The Current State of Immune Checkpoint Inhibitors in the First-Line Treatment of Renal Cancer
Rassy, E., Khoury‐Abboud, R., Ibrahim, N., Assi, T., Aoun, F. Y., & Kattan, J. G. (2018) · Immunotherapy · doi:10.2217/imt-2018-0017 · Cited by 10
Fast Forward — Neoadjuvant Cancer Immunotherapy
Gajewski, T. F. (2018) · New England Journal of Medicine · doi:10.1056/nejme1803923 · Cited by 10
Deutsch, J. S., Wang, D., Chen, K. Y., Cimino‐Mathews, A., Thompson, E. D., Jedrych, J. J., Anders, R. A., Gabrielson, E., Illei, P. B., Uttam, S., et al. (2024) · Laboratory Investigation · doi:10.1016/j.labinv.2024.102166 · Cited by 9
Immune-Based Strategies for Pancreatic Cancer in the Adjuvant Setting
Liang, K.-L., & Azad, N. S. (2025) · Cancers · doi:10.3390/cancers17071246 · Cited by 10
“The rationale for immunotherapy in the neoadjuvant setting may allow for more effective immune recognition of neoantigens leading to increased tumor-specific effector or memory T cells [121].”
Bouguerra, R., Hajji, S. E., Wassmer, C., Bakaric, A., Slits, F., Moeckli, B., Rubbia‐Brandt, L., Lacotte, S., & Toso, C. (2025) · Hepatology · doi:10.1097/hep.0000000000001575 · Cited by 9
Yuan, F., Jing, M., Chen, X., & Zhang, X. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103504 · Cited by 10
“64 Especially in patients with BRAF-mutant melanoma, NT has demonstrated higher efficacy and safety.”
Wang, G., Yoon, D., Nandi, A., Patel, K., Azar, T., Kim, J., Han, N. A., Nickie, A., Park, S., Wang, K., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.12.004 · Cited by 12
Neoadjuvant therapy for melanoma: new and evolving concepts.
Erstad, D. J., Witt, R. G., & Wargo, J. A. (2022) · PubMed · Cited by 11
Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation
Ouranos, K., Chatziioannou, A., Goulis, I., & Sinakos, E. (2022) · World Journal of Transplantation · doi:10.5500/wjt.v12.i11.331 · Cited by 9
Zheng, H., Wu, L., Chen, J., Na, N., & Lou, G. (2024) · Breast Cancer · doi:10.1007/s12282-024-01543-z · Cited by 9
“Previously reported neoadjuvant immunotherapy models were established by transplanting highly metastatic mouse cell lines, such as 4T1 and E0771, orthotopically or subcutaneously into immunocompetent mice [28, 29].”
Current usage of pembrolizumab in triple negative breast cancer (TNBC)
O’Rourke, H., Hart, C. D., & Boer, R. H. D. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2341729 · Cited by 9
“Pre-clinical studies have demonstrated improved immune responses to neoadjuvant versus adjuvant ICIs [18].”
BackgroundKadono, T., Yamamoto, S., & Kato, K. (2024) · Future Oncology · doi:10.1080/14796694.2024.2345043 · Cited by 9
The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer
Alexander, M., Ko, B., Lambert, R., Gadgeel, S. M., & Halmos, B. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1702526 · Cited by 9
“In a triple-negative breast cancer model, combination of neoadjuvant anti-PD-L1/anti-CD137 increased tumor-specific CD8 + T cells in blood even after the tumor was removed [31].”
BackgroundSalgado, E., & Cao, Y. (2020) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2021006 · Cited by 9
Research status on immunotherapy trials of gastric cancer
Liang, C., Wu, H., Yu, W., & Chen, W. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i21.5782 · Cited by 11
Burton, E. M., Amaria, R. N., Cascone, T., Chalabi, M., Gross, N. D., Mittendorf, E. A., Scolyer, R. A., Sharma, P., & Ascierto, P. A. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03472-x · Cited by 10
Kowalczyk, J. T., Fabian, K. P., Padget, M. R., Lopez, D. C., Hoke, A. T. K., Allen, C. T., Hermsen, M. A. J. A., London, N. R., & Hodge, J. W. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005752 · Cited by 9
Cui, H., Liang, W., Cui, J., Song, L., Yuan, Z., Chen, L., & Wei, B. (2023) · Gastroenterology report · doi:10.1093/gastro/goae005 · Cited by 9
“Liu et al. [24] suggested that these clinical benefits could be attributed to the activation of tumor-specific CD8 þ T cells in response to endogenous retroviral antigens, leading to the development of systemic antitumor immunity.”
BackgroundAdvances in immune neoadjuvant/adjuvant therapy‐related adverse events of non‐small cell lung cancer
Zhao, Q., Liu, C., Liu, H., & Chen, J. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13378 · Cited by 9
Rosner, S., & Forde, P. M. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.02.007 · Cited by 9
Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies
Chen, Y., Qi, F., Sun, C., Jiang, P., Xue, X., Yang, X., Li, X., He, X., Wang, Y., & Zhang, T. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241312501 · Cited by 8
A New Era, New Risks: The Cardio-Oncology Perspective on Immunotherapy in Non-Small Cell Lung Cancer
Tarantini, L., Gallucci, G., Inno, A., Camerini, A., Canale, M. L., Larocca, M., Zanelli, F., Pagano, M., Alberti, G., Ciammella, P., et al. (2025) · Cancers · doi:10.3390/cancers17213443 · Cited by 9
Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines
Hannani, D., Leplus, E., Laulagnier, K., Chaperot, L., & Plumas, J. (2023) · Genes & Cancer · doi:10.18632/genesandcancer.229 · Cited by 8
Meng, J., Tan, J. Y., Joseph, C. R., Ye, J., Lim, J. C. T., Goh, D. L. M., Xue, Y., Lim, X., Koh, V. C. Y., Wee, F. Y. T., et al. (2023) · Laboratory Investigation · doi:10.1016/j.labinv.2023.100303 · Cited by 10
Peluso, E., Edwards, W. F., & Janco, J. M. T. (2024) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2024.101371 · Cited by 8
“…undergoing surgery for melanoma, that suggest immunotherapy in the neoadjuvant setting (or with active cancer present) may be more effective due to expansion of existing antitumor T-cells both in the tumor and in circulation, before surgical resection (Liu et al., 2016; Patel et al., 2023).”
BackgroundCurrent status of neoadjuvant immunotherapy for the treatment of gastric cancer
Zhang, X., Лю, Б., Wang, R., Li, X., & Zhou, W. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03437-0 · Cited by 8
“A preclinical study determined that immunotherapy could activate a higher number of CD8 + lymphocytes prior to the surgical intervention compared to post-surgery, implying that the tumor antigen load before the operation is relatively higher before the operation [26].”
Neo-Adjuvant Therapy for Metastatic Melanoma
Kuijpers, A. M. J., & van Akkooi, A. C. J. (2024) · Cancers · doi:10.3390/cancers16071247 · Cited by 10
“However, the pre-clinical models developed by Teng et al. tested NAS immunotherapy first in breast and colorectal cancer in mice and compared it to adjuvant immunotherapy [7].”
MethodHuang, X., Pang, G., Mao, Z., Li, B., Teng, Z., Yang, Y., Qiu, Z., Chen, X., & Wang, P. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.13761 · Cited by 8
Zhang, T., Xie, Q., Chen, W., Liu, X., Zhang, J., Tian, T., Gao, Y., Fu, C., Batur, S., Xu, H., et al. (2024) · Small Methods · doi:10.1002/smtd.202401425 · Cited by 8
Moving Immunotherapy Into Early-Stage Lung Cancer
Linehan, A., & Forde, P. M. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000493 · Cited by 9
Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety
Nebhan, C. A., & Johnson, D. B. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1882856 · Cited by 8
Vathiotis, I. A., Johnson, J. M., Luginbuhl, A., Cognetti, D. M., Curry, J., & Argiris, A. E. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102437 · Cited by 8
Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
Parekh, J., Parikh, K., Reuss, J. E., Friedlaender, A., & Addeo, A. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01430-4 · Cited by 10
Primary tumor resection improves survival benefit of stage IVB cervical carcinoma: a new perspective
He, Y., Zhang, Y., Hu, S., Zhang, B., Zhang, Z., Yao, Y., & Wang, X. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04988-5 · Cited by 8
Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?
Solinas, C., Fumagalli, D., & Dieci, M. V. (2021) · Cancers · doi:10.3390/cancers13071655 · Cited by 8
“, as in the case of a neoadjuvant approach), rather than in their absence [30].”
BackgroundMoving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review
Viscardi, G., Vitiello, F., Servetto, A., Gristina, V., Pizzutilo, E. G., Canciello, M. A., Medusa, P. M., Salomone, F., Guida, G. D., Mollica, M., et al. (2022) · Cancers · doi:10.3390/cancers14235810 · Cited by 8
“Similarly, the combination of antiPD1 and agonistic anti-CD137, to enhance the activity of NK cells [38], promoted longer survival and reduced metastatic burden of TNBC-bearing mice treated before surgery, compared to adjuvant treatment [36].”
BackgroundInfluentialChen, T., & Liu, F. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108588 · Cited by 8
Nardin, C., Cavalieri, C., Lebbé, C., Gerard, É., Puyraveau, M., Vergara, R., Maubec, E., Kramkimel, N., Lesage, C., Rouanet, J., et al. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf268 · Cited by 7
Ospina, A. V., González-Larriba, J. L., Nadal, E., Hernándo, F., Bosch‐Barrera, J., Calvo, V., Bolufer-Nadal, S., de la Cruz, J. L. C.-C., Vidueira, I. M., Álvarez, A., et al. (2025) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-619 · Cited by 7
Neoadjuvant Chemotherapy for Gastric Cancer: Evolving Approaches and Supporting Evidence
Kim, Y. J., Kim, H. R., Hyung, J., & Ryu, M. (2025) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2026.26.e2 · Cited by 7
“…antigen presentation and priming of tumor-specific T cells can generate more durable immune responses [35]; IO may reduce regulatory T-cell infiltration and increase CD8+ T-cell activity within the tumor microenvironment [36,37]; and ICIs may act synergistically with cytotoxic chemotherapy [38-40].”
Yu, C., Zhang, D., Chen, C., Xing, S., Li, P., Zhang, Y., Shang, L., Ma, H., & Zhou, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105191 · Cited by 8
Björkström, K., Matikas, A., Svedman, F. C., Björgvinsson, E., Zupancic, M., Villabona, L. E. E., Eriksson, H., Skribek, M., Fernebro, J., Lindskog, M., et al. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70073 · Cited by 10
Xu, J., Hong, Z.-N., Cai, Y., Chen, Z., Lin, J., Yuan, X., Chen, S., Xie, J., Kang, M., & Ke, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1279733 · Cited by 7
Hampe, L., Küffer, S., Niemeier, T., Scheele, N. C., Hampe, L. Z., Riedl, A. L., Fischer, L. A., Ziegler, D. A., Leu, M., Dröge, L. H., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1509051 · Cited by 7
Neoadjuvant therapy for melanoma: is it ready for prime time?
Helmink, B. A., & Wargo, J. A. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30377-8 · Cited by 7
Advances and controversies in the management of early stage non-small cell lung cancer
Ramos, Á. C., Gutiérrez, E. C., de la Pinta, C., Cortés, L. Q., Sosa‐Fajardo, P., Couñago, F., Mielgo-Rubio, X., & Trujillo-Reyes, J. C. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i12.1089 · Cited by 7
Takenaka, M., Kuroda, K., & Tanaka, F. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02459-y · Cited by 7
“In addition, immunotherapy may be theoretically more effective in preoperative neoadjuvant setting than in postoperative adjuvant setting [73], which was demonstrated in a preclinical study [74].”
Chen, Z., Zou, Z., Qian, M., Xu, Q., Xue, G., Yang, J., Luo, T., Hu, L., & Wang, B. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101955 · Cited by 7
“Liu et al. [31] have demonstrated that neoadjuvant treatments with anti-PD-1 and anti-CD137 therapies could contribute to a stronger expansion of tumor-specific CD8 + T cells in the blood and peripheral organs in a mouse breast cancer model; more than 50 % of mice treated with the combination…”
BackgroundPACIFIC: Time for a surgical IIIA uprising
Pass, H. I. (2018) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2018.05.059 · Cited by 7
Beyond Ipilimumab: a review of immunotherapeutic approaches in clinical trials in melanoma
Middleton, G. (2020) · Immunotherapy Advances · doi:10.1093/immadv/ltaa010 · Cited by 7
“Liu and colleagues compared neoadjuvant with adjuvant Treg depletion or anti-PD-1 mAb/anti-CD137 mAb in two breast cancer mouse models [2].”
BackgroundAdjuvant and Neoadjuvant Therapies in Cutaneous Melanoma
Ponto, J., & Bell, R. B. (2022) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2021.11.010 · Cited by 8
Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer
Bell, R. B., Gough, M. J., Crittenden, M. R., & Young, K. H. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162733 · Cited by 8
Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward
Shinada, K., & Murakami, S. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s399657 · Cited by 7
Germline mechanisms of immunotherapy toxicities in the era of genome‐wide association studies
Gusev, A. (2023) · Immunological Reviews · doi:10.1111/imr.13253 · Cited by 8
Spillane, A. J., Menzies, A. M., & van Akkooi, A. C. J. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08566-8 · Cited by 8
Kadmiri, M. A. A. E., & Rajan, A. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.08.39 · Cited by 7
Liu, S., Knochelmann, H. M., Lomeli, S. H., Hong, A., Richardson, M., Yang, Z., Lim, R., Wang, Y., Dumitras, C., Krysan, K., et al. (2021) · immuneACCESS · doi:10.21417/sl2021crm · Cited by 7
Intratumoral immunotherapy prior to cancer surgery, a promising therapeutic approach
Silihe, K. K., & Fiering, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1545000 · Cited by 6
Fu, Z., Dong, X., Sun, J., Deng, W., Zhao, Y., Yang, D., Jiang, L., Chang, X., Yu, R., Shi, A., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1602082 · Cited by 6
Brenner, R. M., Edri, H. T. F., Sarel, I., Левко, А. А., Turaieva, S., Tairov, T. N., Berezhnov, I., Fenig, S., Fenig, E., Ziv‐Baran, T., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1691000 · Cited by 6
“To Anticipate”: Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers
Garutti, M., Buriolla, S., Bertoli, E., Vitale, M. G., Rossi, E., Schinzari, G., Minisini, A. M., & Puglisi, F. (2020) · Cancers · doi:10.3390/cancers12071941 · Cited by 7
“In particular, the percentage of patients with brisk TILs (defined as lymphocytes diffusely infiltrating the invasive component of the tumor) increased after treatment, with a significant improvement in 1-y RFS (89% vs. 27% in non-brisk TIL patients) [44].”
BackgroundResultInfluentialAdugna, A., Muche, Y., Jemal, M., Habtegiorgis, S. D., Belew, H., & Amare, G. A. (2024) · Aging Medicine · doi:10.1002/agm2.12292 · Cited by 6
“58,60 In a retrospective analysis, 5-year over-survival rates for neoadjuvant immunotherapy therapy and adjuvant immunotherapy therapy were 56.2% and 33.0%, respectively.”
BackgroundInfluentialZhao, Y., & Wucherpfennig, K. W. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001023 · Cited by 6
Tissue-Resident Memory T Cells in Cancer Metastasis Control
Montgomery, T., Master, A. P., Jin, Z., Shi, Q., Lai, Q., Desai, R., Zhang, W., Maharjan, C. K., & Kolb, R. H. (2025) · Cells · doi:10.3390/cells14161297 · Cited by 7
“Neoadjuvant ICI—treating cancer patients with ICI prior to surgical intervention—shows clear promise as an approach for metastasis prevention and control and may even outperform standard adjuvant ICI therapy in metastatic cancers [47].”
He, X., Xu, Y., Ren, Y., Wang, J., Ni, Y., Zheng, Y., Wang, Y., Ding, X., Li, Y., & Zhu, H. (2025) · Oral Oncology · doi:10.1016/j.oraloncology.2025.107744 · Cited by 7
Gronchi, A. (2013) · PubMed · Cited by 6
Sim, J. K., Choi, J., & Lee, S. Y. (2023) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2023.345 · Cited by 7
Gu, C., Teng, X., Sun, X., Liu, J.-C., Zhu, Z., Zhang, L., Wu, Z., Zou, R., Pang, J., & Lyu, X. (2024) · BMC Cancer · doi:10.1186/s12885-024-12333-3 · Cited by 7
“Previous studies have demonstrated that the efficacy of neoadjuvant immunotherapy relies on CD8 + T cells and IFN [24].”
BackgroundSelf-citationEmerging Indications for Neoadjuvant Systemic Therapies in Cutaneous Malignancies
Lins, D. S. D. R., Awni, B. M., Pereira, A. Z. L., de Menezes, J. N., Bertolli, E., Belfort, F. A., & Munhoz, R. R. (2024) · Medical Sciences · doi:10.3390/medsci12030035 · Cited by 6
“Both preclinical and translational studies provide a strong rationale supporting these premises, particularly in respect of immunotherapy [26].”
BackgroundInfluentialDing, S., Wu, C., Cao, J., & Lyu, J. (2024) · Current Urology · doi:10.1097/cu9.0000000000000263 · Cited by 6
Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?
Heigener, D. F., & Reck, M. (2019) · Drugs · doi:10.1007/s40265-019-01222-w · Cited by 6
Neoadjuvant Therapy for Melanoma
Lowe, M., & Kudchadkar, R. R. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2020.03.001 · Cited by 7
Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift?
Seckler, F., Doussot, A., Colpart, P., Turco, C., Calame, P., Aubin, F., Algros, M. P., Borg, C., Nardin, C., & Heyd, B. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.05.048 · Cited by 6
Neoadjuvant immunotherapy in nonsmall cell lung cancer
Pall, G. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000699 · Cited by 6
“studies were published in 2016 [6] showing that neoadjuvant administration of checkpoint inhibitors led to improved survival results when compared with the adjuvant application.”
[Hepatocellular carcinoma immune microenvironment].
Miao, T. G., & Nan, Y. M. (2022) · PubMed Central · doi:10.3760/cma.j.cn501113-20220703-00365 · Cited by 10
Wei, B., Jin, X., Lu, G., Zhao, T., Xue, H., & Zhang, Y. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02341-7 · Cited by 8
Zijlker, L. P., Chen, H., Spillane, A. J., Gonzalez, M., Pennington, T. E., Menzies, A. M., Lo, S., Ferguson, P. M., Rawson, R. V., Colebatch, A. J., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15274-0 · Cited by 6
Ren, Y., Tang, H., Zhang, J., She, Y., Sun, X., Xie, D., & Chen, C. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920973567 · Cited by 8
Wang, K., Cui, T.-Y., Yang, X., Wang, G.-Q., Jiang, Q.-S., Sun, H., Jiang, N., Yong, X., Shi, C., Ding, Y.-B., et al. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s316288 · Cited by 6
Cheng, Z., Du, Y., Yu, L., Zhu, Y., & Tian, J. (2022) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01688-9 · Cited by 6
Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better?
Perez‐Gracia, J. L., Sanmamed, M. F., & Melero, I. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.10.12 · Cited by 6
Zhang, Z., Sui, D., Xu, M., Yang, L., Lai, C., Ji, Y., & Wang, K. (2024) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.4c03274 · Cited by 5
Liu, J.-C., Wu, Z., Zhou, S., Lv, W., Wang, Y., Xia, P., Zhu, L., & Hu, J. (2025) · European journal of medical research · doi:10.1186/s40001-025-02599-z · Cited by 5
“In recent years, immune checkpoint inhibitors (ICIs) have made progresses in the treatment of multiple solid tumors [9, 10].”
Self-citationWang, M., Ran, C., & Liu, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1674174 · Cited by 5
Xiang, J., Zhang, J., Tian, D., Zhang, L., Xu, Y., & Lu, X. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003231 · Cited by 5
“The expression of PD-L1 on the surface of tumors [ 61 , 65 ] , along with characteristics inherent to the tumor microenvironment [ 56 , 136 ] , has been recognized as crucial predictors for the effectiveness of [ 56 ] 2016 638 Pan-cancer Anti-mouse antibody”
Neoadjuvant Treatment Approaches to Oral Cancer
Siafa, L., Ali, A. H., Kerr, P., Pathak, A., Viallet, N. R., Lane, C. F., & Sayed, S. I. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196883 · Cited by 6
“These theoretical benefits are supported by studies in melanoma and breast cancer [3,27,28].”
Metzger, D. A., Chahal, Y., Watman, O. F., Li, Y., Pigazzi, A., Siolas, D., & Jafari, M. D. (2025) · Cancers · doi:10.3390/cancers17213496 · Cited by 5
“In addition, data from animal models suggest that immunotherapy induces a greater T cell response when administered prior to resection [20,21].”
Metadata
- Authors
- Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., & Teng, M. W. L.
- Affiliations
- The University of Queensland (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Juntendo University (JP)
- 1Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
- Corresponding author
- Teng, Michele W.L.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2016-12-01
- Volume
- 6
- Issue
- 12
- Pages
- 1382-1399
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2521503673
- Cited by
- 894
- References
- 55
- Citations by year
- 2026: 86 · 2025: 91 · 2024: 135 · 2023: 112 · 2022: 113 · 2021: 112 · 2020: 101 · 2019: 65 · 2018: 50 · 2017: 23 · 2016: 1
- FWCI
- 24.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (15K14410)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- neoadjuvant immunotherapy, adjuvant immunotherapy, metastatic breast cancer, primary tumor resection, tumor-specific immunity, CD8+ T cells, predictive biomarkers
- MeSH terms
- Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Immunotherapy, Neoplasm Metastasis, Treatment Outcome, Chemotherapy, Adjuvant, CD8-Positive T-Lymphocytes, Neoadjuvant Therapy, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.